Greenwich Lifesciences Inc (NASDAQ: GLSI) — Perfil da empresa, notícias e dados financeiros
Greenwich Lifesciences develops therapies for breast cancer, focusing on immunotherapy to improve patient quality of life.

Greenwich Lifesciences Inc
Greenwich Lifesciences (NASDAQ:GLSI) is a biopharmaceutical enterprise focused on the development and commercialization of therapeutics for breast cancer patients. The core of its operations lies in advancing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. With a clear objective to enhance survival rates and quality of life for breast cancer sufferers, the company leverages cutting-edge scientific research to push the boundaries of treatment possibilities. Greenwich Lifesciences is dedicated to bringing novel, life-saving therapies to market, aiming to transform the landscape of cancer care for women worldwide.
Resumo
Operações
Produtos e/ou serviços de Greenwich Lifesciences Inc
- GP2 is a novel immunotherapy for preventing breast cancer recurrence.
- Research into immunotherapies targeting various cancer types.
- Development of precision medicine techniques for cancer treatment.
- Collaboration with academic and research institutions to advance cancer immunotherapy studies.
- Involvement in clinical trials to test the efficacy and safety of new cancer treatments.
- Providing educational resources and support for cancer patients and healthcare professionals.
equipe executiva do Greenwich Lifesciences Inc
- Snehal S. PatelCEO, CFO & Director
- Eric RotheFounder & Independent Director
- Frank Joseph DaughertyChief Medical Officer & Director
- Jaye L. ThompsonVice President Clinical & Regulatory Affairs
- Christine T. FischetteVP of Business Development
Últimas notícias sobre a Greenwich Lifesciences Inc
Greenwich LifeSciences adds up to 10 UK sites
United StatesGreenwich LifeSciences reports 70% reduction in recurrence rate
United StatesGreenwich LifeSciences unifies 180-site breast cancer trial
United StatesGreenwich LifeSciences secures European approval for Phase 3 asset lot
United StatesGreenwich LifeSciences reports rising immune responses in Phase III breast cancer trial
United StatesGreenwich LifeSciences reports significant immune response in Phase III breast cancer trial
United States
Comunicados recentes
O que a Greenwich Lifesciences Inc (GLSI) comunicou ao mercado, do mais recente para o mais antigo.
Principais indicadores financeiros
Resultados divulgados pela Greenwich Lifesciences Inc, em USD.
- Cap. de mercado
- 302,1 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -19,4 mi | -19,4 mi | |
| 0 | -17,6 mi | -17,4 mi | |
| 0 | -9,3 mi | -8,9 mi | |
| 0 | -8 mi | -7,8 mi |